These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 16602095)

  • 1. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.
    Tomoeda K; Awata H; Matsuura T; Matsuda I; Ploechl E; Milovac T; Boneh A; Scott CR; Danks DM; Endo F
    Mol Genet Metab; 2000 Nov; 71(3):506-10. PubMed ID: 11073718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.
    Lock EA; Gaskin P; Ellis M; Provan WM; Smith LL
    Toxicol Appl Pharmacol; 2006 Aug; 215(1):9-16. PubMed ID: 16580702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the tyrosine aminotransferase cDNA and genomic DNA sequences of normal mink and mink affected with tyrosinemia type II.
    Leib SR; McGuire TC; Prieur DJ
    J Hered; 2005; 96(4):302-9. PubMed ID: 15817712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
    Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
    Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
    Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
    Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary tyrosinemia type I--an overview.
    Kvittingen EA
    Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathophysiology and treatment of hereditary tyrosinemia type 1.
    Grompe M
    Semin Liver Dis; 2001 Nov; 21(4):563-71. PubMed ID: 11745044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosinemia type II (Richner-Hanhart syndrome): a new mutation in the TAT gene.
    Culic V; Betz RC; Refke M; Fumic K; Pavelic J
    Eur J Med Genet; 2011; 54(3):205-8. PubMed ID: 21145993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
    Al-Dhalimy M; Overturf K; Finegold M; Grompe M
    Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and mutational investigations of tyrosinemia type II in Northern Tunisia: identification and structural characterization of two novel TAT mutations.
    Charfeddine C; Monastiri K; Mokni M; Laadjimi A; Kaabachi N; Perin O; Nilges M; Kassar S; Keirallah M; Guediche MN; Kamoun MR; Tebib N; Ben Dridi MF; Boubaker S; Ben Osman A; Abdelhak S
    Mol Genet Metab; 2006 Jun; 88(2):184-91. PubMed ID: 16574453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The narrow substrate specificity of human tyrosine aminotransferase--the enzyme deficient in tyrosinemia type II.
    Sivaraman S; Kirsch JF
    FEBS J; 2006 May; 273(9):1920-9. PubMed ID: 16640556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
    Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
    Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
    Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
    J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.
    Lock EA; Gaskin P; Ellis MK; Robinson M; Provan WM; Smith LL
    Toxicol Appl Pharmacol; 1998 May; 150(1):125-32. PubMed ID: 9630461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.
    Vogel A; van Den Berg IE; Al-Dhalimy M; Groopman J; Ou CN; Ryabinina O; Iordanov MS; Finegold M; Grompe M
    Hepatology; 2004 Feb; 39(2):433-43. PubMed ID: 14767996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of homogentisate-treated Fah-/- Hpd-/-mice using DNA microarrays.
    Tanaka Y; Nakamura K; Matsumoto S; Kimoto Y; Tanoue A; Tsujimoto G; Endo F
    Mol Genet Metab; 2006 Nov; 89(3):203-9. PubMed ID: 16899383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
    Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
    J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
    Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD
    Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.